NO952900L - Materiale inneholdende tandospiron eller analoger derav - Google Patents

Materiale inneholdende tandospiron eller analoger derav

Info

Publication number
NO952900L
NO952900L NO952900A NO952900A NO952900L NO 952900 L NO952900 L NO 952900L NO 952900 A NO952900 A NO 952900A NO 952900 A NO952900 A NO 952900A NO 952900 L NO952900 L NO 952900L
Authority
NO
Norway
Prior art keywords
analogs
material containing
tandospirone
containing tandospirone
patient
Prior art date
Application number
NO952900A
Other languages
English (en)
Norwegian (no)
Other versions
NO952900D0 (no
Inventor
Atul D Ayer
Dana Ridzon
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO952900D0 publication Critical patent/NO952900D0/no
Publication of NO952900L publication Critical patent/NO952900L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO952900A 1993-01-27 1995-07-21 Materiale inneholdende tandospiron eller analoger derav NO952900L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/010,086 US5330762A (en) 1992-02-27 1993-01-27 Tandospiaine antidepressive therapy
PCT/US1993/009627 WO1994016699A1 (en) 1993-01-27 1993-10-08 Compositions containing tandospirone or its analogs

Publications (2)

Publication Number Publication Date
NO952900D0 NO952900D0 (no) 1995-07-21
NO952900L true NO952900L (no) 1995-09-26

Family

ID=21743762

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952900A NO952900L (no) 1993-01-27 1995-07-21 Materiale inneholdende tandospiron eller analoger derav

Country Status (16)

Country Link
US (1) US5330762A (de)
EP (1) EP0681473B1 (de)
JP (1) JPH08505869A (de)
KR (1) KR100293305B1 (de)
AT (1) ATE173926T1 (de)
AU (1) AU674898B2 (de)
CA (1) CA2152673A1 (de)
DE (1) DE69322411T2 (de)
DK (1) DK0681473T3 (de)
ES (1) ES2125354T3 (de)
FI (1) FI953566A7 (de)
MX (1) MX9304365A (de)
NO (1) NO952900L (de)
NZ (1) NZ257244A (de)
WO (1) WO1994016699A1 (de)
ZA (1) ZA937746B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609094D0 (en) * 1996-05-01 1996-07-03 Univ Strathclyde Delivery device
EP1428535A1 (de) * 1998-11-02 2004-06-16 ALZA Corporation Kontrollierte Freigabe von Antidepressiva
DE69930952T2 (de) * 1998-11-02 2006-08-31 Alza Corp., Mountain View Verfahren und Vorrichtung zur kontrollierten Abgabe pharmazeutischer Mittel sowie Dosierungsform hierfür
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
EP1495000A4 (de) * 2002-04-08 2005-10-05 Ranbaxy Lab Ltd Als uroselektive a1a-adrenozeptorblocker geeignete alpha,omega-dicarboximidderivate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7892472B2 (en) 2004-08-12 2011-02-22 United States Gypsum Company Method of making water-resistant gypsum-based article
US20060247249A1 (en) * 2005-11-16 2006-11-02 Mohammad Salman Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
EP2429514A1 (de) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Zusammensetzungen mit transnorsertralin- und serotoninrezeptor-1a-agonisten/antagonisten und ihre verwendung
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126865A (ja) * 1981-12-22 1983-07-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPS5976059A (ja) * 1982-10-21 1984-04-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same

Also Published As

Publication number Publication date
FI953566L (fi) 1995-07-26
ES2125354T3 (es) 1999-03-01
NZ257244A (en) 1996-10-28
ZA937746B (en) 1994-08-10
DE69322411D1 (de) 1999-01-14
KR960700058A (ko) 1996-01-19
AU674898B2 (en) 1997-01-16
ATE173926T1 (de) 1998-12-15
FI953566A0 (fi) 1995-07-26
JPH08505869A (ja) 1996-06-25
KR100293305B1 (ko) 2001-09-17
AU5354594A (en) 1994-08-15
FI953566A7 (fi) 1995-07-26
US5330762A (en) 1994-07-19
DE69322411T2 (de) 1999-04-29
EP0681473B1 (de) 1998-12-02
DK0681473T3 (da) 1999-08-16
NO952900D0 (no) 1995-07-21
EP0681473A1 (de) 1995-11-15
CA2152673A1 (en) 1994-08-04
WO1994016699A1 (en) 1994-08-04
MX9304365A (es) 1994-07-29

Similar Documents

Publication Publication Date Title
MX171191B (es) Composiciones farmaceuticas de glipizida
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO173998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO169347C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
SE8600632D0 (sv) Novel pharmaceutical composition
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
DE3566404D1 (en) Substituted benzopyrans, process for their preparation and their use in medicines
NO952900D0 (no) Kompositt inneholdende tandospiron eller analoger av samme
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
DE69522827D1 (de) Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate
NO301760B1 (no) Farmakologisk aktive <alfa>-[tertiær-aminometyl]-benzenmetanolderivater, farmasöytiske preparater inneholdende disse samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
ATE130192T1 (de) Verwendung von 15-deoxyspergualin als arzneimittel.
DK614989A (da) Indolderivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
DK456389A (da) Broforbundne bicycliske imider med en 4-oe4-(3-benzisothiazolyl)-1-piperazinylaabutylgruppe knyttet til imidnitrogenatomer og antipsykotisk farmaceutiske praeparater indeholdende disse
SE8704049D0 (sv) Novel pharmacological compounds
DK0527720T3 (da) Terapeutiske midler
MX9306998A (es) Una composicion terapeutica de tandospirona y forma de dosis paraadministrarla.